<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44854">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02522377</url>
  </required_header>
  <id_info>
    <org_study_id>Ketamine ECT</org_study_id>
    <nct_id>NCT02522377</nct_id>
  </id_info>
  <brief_title>Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression</brief_title>
  <official_title>Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients With Treatment Resistant Depression: A Double Blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this proof of concept study, the investigators plan to administer iv ketamine interleaved
      with ECT days.

      Patients with treatment resistant depression who are deemed to be eligible for ECT treatment
      will randomly be assigned to either ketamine or active placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will compare the effects of standard ketamine dosing with an active placebo arm.

      Hypothesis 1:

      The investigators hypothesize that interleaved Electroconvulsive Treatment and active
      ketamine treatment will lead to a meaningful clinical improvement compared to
      Electroconvulsive Treatment and placebo treatment arm.

      Hypothesis 2:

      The investigators hypothesize that interleaved Electroconvulsive Treatment and active
      ketamine treatment will attenuate cognitive side effects.

      Methods and Design:

      Patients with treatment resistant depression who are deemed to be eligible for
      Electroconvulsive Treatment will randomly be assigned to either ketamine or active placebo

      Electroconvulsive Treatments:

      All patients (independent of their depression scores) will receive the same
      Electroconvulsive Treatment parameters: Bi-frontal brief pulse (0.5 miliseconds)
      Electroconvulsive Treatment administered by using Thymatron Electroconvulsive Treatment
      machine.

      Study blinding:

      Neither the patients, nor the treating psychiatrist or the nurse will be aware of the
      patient's assigned arm. The success of blinding will be tested after each ketamine treatment
      with a questionnaire given to the subject, raters, and treating physician.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>visit 17</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <condition>Severe Depression</condition>
  <arm_group>
    <arm_group_label>Ketamine Infusions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are randomized to be on this group will receive a standard dose of ketamine interleaved with Electroconvulsive Treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>inter venous injections</description>
    <arm_group_label>Ketamine Infusions</arm_group_label>
    <other_name>Ketalar</other_name>
    <other_name>Calypsol</other_name>
    <other_name>Ketanest</other_name>
    <other_name>Tekam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>inter venous injections</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Dormicum</other_name>
    <other_name>Hypnovel</other_name>
    <other_name>Versed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males/females at least 18 years of age but no older than 65 years of age

          2. Meet Diagnostic and Statistical Manual of Mental Disorders-4th Edition (DSM-IV)
             criteria for Major Depression or Bipolar Disorder, depressed phase, as determined by
             a clinician's diagnostic evaluation and confirmed by interview using the Mini
             International Neuropsychiatric Interview (MINI PLUS 5.0.0)

          3. A current depressive episode that has lasted a minimum of 4 weeks.

          4. Have &gt; 3 trials of antidepressants/augmentation strategies.

          5. Have a support system capable of transporting the patient post-treatment.

        Exclusion Criteria:

          1. Meeting Diagnostic and Statistical Manual of Mental Disorders criteria for
             schizophrenia, schizophreniform disorder, schizoaffective disorder, mental
             retardation, pervasive developmental disorder.

          2. Meeting Diagnostic and Statistical Manual of Mental Disorders criteria for other
             substance/alcohol dependence within the past 6 months or abuse in the past 3 months.

          3. Patients who meet exclusion criteria for ketamine and/or midazolam infusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murat Altinay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Murat Altinay, MD</last_name>
    <phone>216-445-3359</phone>
    <email>altinam@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy L Morrison</last_name>
    <phone>216-445-2378</phone>
    <email>morrisa15@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation Center for Behavioral Health</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murat Altinay, MD</last_name>
      <phone>216-445-3359</phone>
      <email>altinam@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Amy L Morrison</last_name>
      <phone>216-445-2378</phone>
      <email>morrisa15@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Murat Altinay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 17, 2017</lastchanged_date>
  <firstreceived_date>August 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Dr. Murat Altinay</investigator_full_name>
    <investigator_title>Staff</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Electroconvulsive Therapy</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Treatment Resistant Depression</keyword>
  <keyword>electroconvulsive treatment</keyword>
  <keyword>Severe depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
